Clonogenic assay for urologic malignancies.

Gan Pub Date : 1984-08-01
T Hashimura, N Tanigawa, K Okada, O Yoshida
{"title":"Clonogenic assay for urologic malignancies.","authors":"T Hashimura,&nbsp;N Tanigawa,&nbsp;K Okada,&nbsp;O Yoshida","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>An in vitro double soft agar technique was used to culture 91 human urologic tumors including 37 renal cell, 40 uroepithelial, 7 prostatic and 7 testicular cancers. Cells from 31 of 37 renal, 32 of 40 uroepithelial, 3 of 7 prostatic and 4 of 7 testicular cancer specimens grew to the extent that they could be used in chemosensitivity testing in soft agar (greater than or equal to 30 colonies per control plate). With this assay system, a very high growth rate (70/91; 77%) was obtained. The in vitro response rates of greater than or equal to 10% were noted with mitomycin C, 5-fluorouracil, cisplatin, bleomycin and vincristine in renal cell cancers, and with vincristine and cisplatin in uroepithelial cancers. Drug sensitivity studies showed that the rates of in vitro sensitivity of uroepithelial cancers were close to those obtained in general clinical experience, while the rates of the vitro sensitivity of renal cell cancers were considerably higher than the rates found clinically. It is concluded from this study that in vitro chemosensitivity testing by clonogenic assay is likely to be a useful tool in the treatment of urologic cancers, but that a simple definition of sensitivity cannot be applied for all types of tumors.</p>","PeriodicalId":12660,"journal":{"name":"Gan","volume":"75 8","pages":"724-8"},"PeriodicalIF":0.0000,"publicationDate":"1984-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gan","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

An in vitro double soft agar technique was used to culture 91 human urologic tumors including 37 renal cell, 40 uroepithelial, 7 prostatic and 7 testicular cancers. Cells from 31 of 37 renal, 32 of 40 uroepithelial, 3 of 7 prostatic and 4 of 7 testicular cancer specimens grew to the extent that they could be used in chemosensitivity testing in soft agar (greater than or equal to 30 colonies per control plate). With this assay system, a very high growth rate (70/91; 77%) was obtained. The in vitro response rates of greater than or equal to 10% were noted with mitomycin C, 5-fluorouracil, cisplatin, bleomycin and vincristine in renal cell cancers, and with vincristine and cisplatin in uroepithelial cancers. Drug sensitivity studies showed that the rates of in vitro sensitivity of uroepithelial cancers were close to those obtained in general clinical experience, while the rates of the vitro sensitivity of renal cell cancers were considerably higher than the rates found clinically. It is concluded from this study that in vitro chemosensitivity testing by clonogenic assay is likely to be a useful tool in the treatment of urologic cancers, but that a simple definition of sensitivity cannot be applied for all types of tumors.

泌尿系统恶性肿瘤的克隆测定。
采用体外双软琼脂技术培养了91例人泌尿系统肿瘤,其中肾细胞癌37例,尿上皮癌40例,前列腺癌7例,睾丸癌7例。37例肾癌标本中的31例、40例尿路上皮标本中的32例、7例前列腺癌标本中的3例和7例睾丸癌标本中的4例的细胞生长到可以在软琼脂中用于化学敏感性测试的程度(每个对照板大于或等于30个菌落)。使用该检测系统,生长速度非常高(70/91;77%)。丝裂霉素C、5-氟尿嘧啶、顺铂、博来霉素和长春新碱治疗肾细胞癌的体外反应率大于或等于10%,长春新碱和顺铂治疗尿上皮癌的体外反应率大于或等于10%。药物敏感性研究表明,尿路上皮癌的体外敏感性与一般临床经验接近,而肾细胞癌的体外敏感性明显高于临床发现的比率。从本研究中可以得出结论,体外化学敏感性试验通过克隆测定可能是一个有用的工具,在泌尿系统癌症的治疗,但敏感性的一个简单的定义不能适用于所有类型的肿瘤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gan
Gan
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信